Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 20/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3467240 | 0.94 | TRPV1 (0.87) | TRPV1 | |
| SCHEMBL2523192 | 0.93 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL2530165 | 0.93 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL2526656 | 0.93 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL2525208 | 0.87 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL2524969 | 0.86 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL14797691 | 0.86 | TRPV1 (0.81) | TRPV1 | |
| SCHEMBL15834430 | 0.85 | TRPV1 (0.88) | TRPV1 | |
| SCHEMBL2522985 | 0.85 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL2528530 | 0.85 | TRPV1 (1.00) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252816-B2 | [1] N-(2-fluoro-4-(1-oxo-1-((2-(4-(N-phenylpropionamido)piperidin-1-yl)-6-(trifluoro-methyl)pyridin-3-yl)methylamino)propan-2-yl)phenyl)-N-(methylsulfonyl)propionamide; for treating acute pain, chronic pain, neuropathic pain and visceral pain; neurodegenerative disease, airway diseases | GRUENENTHAL GMBH (DE) | 2012-08-28 | — | — | US | claimed |
| EP-2146959-A1 | VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2010-01-27 | — | — | EP | claimed |
| US-20080269289-A1 | Vanilloid receptor ligand compounds, pharmaceutical compositions containing them, a method of producing them and the use thereof to treat pain and various other conditions | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | claimed |
| WO-2008125296-A1 | VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2008-10-23 | — | — | WO | claimed |
| US-8642623-B2 | Vanilloid receptor ligand compounds, pharmaceutical compositions containing them, a method of producing them and the use thereof to treat pain and various other conditions | GRUENENTHAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| EP-2146959-B1 | VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | GRUENENTHAL GMBH (DE) | 2013-06-19 | — | — | EP | disclosed |
| US-20120302602-A1 | Vanilloid Receptor Ligand Compounds, Pharmaceutical Compositions Containing Them, a Method of Producing Them and the Use Thereof to Treat Pain and Various Other Conditions | GRUENENTHAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-8252816-B2 | [1] N-(2-fluoro-4-(1-oxo-1-((2-(4-(N-phenylpropionamido)piperidin-1-yl)-6-(trifluoro-methyl)pyridin-3-yl)methylamino)propan-2-yl)phenyl)-N-(methylsulfonyl)propionamide; for treating acute pain, chronic pain, neuropathic pain and visceral pain; neurodegenerative disease, airway diseases | GRUENENTHAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| EP-2146959-A1 | VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080269289-A1 | Vanilloid receptor ligand compounds, pharmaceutical compositions containing them, a method of producing them and the use thereof to treat pain and various other conditions | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008125296-A1 | VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269289-A1 | Vanilloid receptor ligand compounds, pharmaceutical compositions containing them, a method of producing them and the use thereof to treat pain and various other conditions | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885 |
| US-20120302602-A1 | Vanilloid Receptor Ligand Compounds, Pharmaceutical Compositions Containing Them, a Method of Producing Them and the Use Thereof to Treat Pain and Various Other Conditions | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.